Purpose: Parameter identifiability and confidence intervals were determined using a profile likelihood (PL) analysis method in a quantification model of the cerebral metabolic rate of oxygen consumption (CMRO 2 
INTRODUCTION
The oxygen metabolism is altered by many neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease (1) (2) (3) (4) (5) (6) (7) (8) (9) , or in brain tumors (10) (11) (12) (13) (14) . For a quantitative analysis of the metabolism of these diseases, an imaging method would be desirable that can map the local cerebral metabolic rate of oxygen consumption (CMRO 2 ). The only clinically established method for direct oxygen quantification is positron emission tomography (PET) with the oxygen isotope 15 O (3, 4, 10, (15) (16) (17) (18) ; however, it is rarely used due to the short isotope half-life of only 2 min, which requires costly on-site production. As an alternative, many indirect methods for CMRO 2 imaging with 1 H MRI have been proposed (19) (20) (21) (22) (23) (24) (25) . Yet, the detection of the MR accessible stable oxygen isotope 17 O is preferable for CMRO 2 quantification as it can directly detect the metabolic end product H 2 17 O. To calculate metabolic rates of oxygen consumption in humans, the 17 O MRI signal changes from H 2 17 O molecules are observed during and after inhalation of isotope-enriched 17 O gas (26) (27) (28) (29) (30) (31) (32) (33) . Direct 17 O MRI and MR spectroscopy has been predominantly performed at ultra-high magnetic fields (UHFs) of 7T and 9.4T (26) (27) (28) (29) (32) (33) (34) (35) (36) . UHFs are advantageous for 17 O MRI because they partly compensate for the low MR sensitivity of the 17 O isotope which is only about 1.1 Á 10 À5 of 1 H due to the low natural abundance of 17 O nucleus of 0.037% and the approximately sevenfold lower gyromagnetic ratio. Unfortunately, UHF MR systems are not widely available and are not yet used in clinical routine. Recently, feasibility of direct 17 O MRI in human brain and heart at clinical field strengths of 3T has been reported (37) , which has the ultimate goal of implementing CMRO 2 quantification at clinical MR systems. In the previous studies, a rebreathing (RB) system was implemented for efficient usage of rare and expensive 17 O 2 gas by re-inhalation of the stored 17 O 2 gas in subsequent inhalation cycles (27, 33) . Unfortunately, this delivery method leads to uncertainties in the determination of the 17 O enrichment fraction of the inhaled gas, which in turn can lead to systematic errors in the quantities derived from this enrichment fraction.
Our objective was to exploit the method of profile likelihood (PL) to determine parameter identifiability and their confidence intervals (CIs) in a nonlinear CMRO 2 quantification model. Using a recently proposed mathematical modeling framework (38) , likelihood-based CIs are considered instead of CIs based on Fisher information which cannot be applied for nonlinear CMRO 2 quantification models with sparsely sampled 17 O signaltime curves (39) . The likelihood-based CI for a parameter is determined by scanning the particular parameter along its axis while reoptimizing all other parameters in the model (see below for a detailed description), thereby revealing nonlinear relations between parameters. Unlike Fisher-based CIs, a parameter profile can become flat as the parameter is driven to its boundaries, indicating that the model structure has to be altered or that additional measurements are required. The parameter is identifiable if the likelihood-based CI is finite. If the CI is infinitely extended in one or two directions, the parameter is practically or structurally non-identifiable, respectively.
Because the proposed modeling framework does not require an analytical solution of differential equations for the CMRO 2 rates, more complex input functions can be used for the 17 O enrichment fraction. Based on the parameter profiles of the amended pharmacokinetic model, the amount of prior information is analyzed that is crucial for the identifiability of the CMRO 2 . In addition, the dependence of the CMRO 2 uncertainty on the confidence of the prior information is calculated. with the assumption of Gaussian errors e $ Nð0; s 2 Þ, which is valid if the signal-to-noise ratio (SNR) of the MR images satisfies at least SNR > 2 (40) . To compare the model response to the measured data, the scaled loglikelihood is calculated via
THEORY
The optimal parameter setû is estimated through minimization of x 2 ðuÞ. To estimate parameter uncertainties, the PL approach is used (41, 42) . Herein, the PL of parameter u j is defined as
The CI of parameter u j is then given by all parameter values for which the corresponding likelihood value does not exceed the threshold denoted by D CL , the x 2 distribution with one degree of freedom and confidence level CL (42):
From the CI, fundamental information about the identifiability of parameters can be derived and results in an infinite CI. A flat parameter profile renders the particular parameter as structurally non-identifiable. In this case, either no information about the parameter is contained in the measurements, or the other parameters can fully compensate if the parameter value is fixed. On the other hand, a parameter profile which exceeds the threshold given by D CL in maximal one direction renders the parameter practically non-identifiable (41) . Here, the data possess insufficient information to restrict the parameter to a finite CI. Whereas structural nonidentifiabilities can be resolved by fixing model parameters, e.g. through prior knowledge, elimination of practical nonidentifiabilities requires additional information through new experiments. Once the quantification model is modified, the improvement over the original model needs to be determined. For this, the statistical significance of the model change is quantified by the likelihood ratio (LR) test (43) . Therein, a null hypothesis H 0 : u 0 is compared with an alternative hypothesis H 1 : u 1 , with u 0 2 u 1 . As the negative log-likelihood in Equation [3] is minimized, the LR is transformed into differences of x 2 values. The test statistic reads
Similar to parameter profiles, the test statistic is asymptotically x 2 -distributed (44) with n dof degrees of freedom according to the difference in dimensionality of both parameter sets: n dof ¼ n u1 À n u0 . Based on x 2 n dof , a P value can be assigned, and the new model is rated an improvement over the original one if P < 0.05.
METHODS

O MRI Measurement
17
O MRI data sets from one volunteer were acquired in two dynamic 17 O 2 inhalation experiments (Exp1 and Exp2) on a clinical 3T MR system (Magneton TIM Trio; Siemens Healthcare, Erlangen, Germany) with a custom-built Tx/Rx 17 O volume head coil. This four-leg low-pass birdcage coil was tuned to the 17 O resonance at f 0 ¼ 16.7 MHz and was driven in a linear mode as described previously (30) . For dynamic data acquisition, a three-dimensional (3D) ultrashort echo time density-adapted radial acquisition technique (45) was employed, with a nominal spatial resolution Dx of 10 mm (Exp1) and 8 mm (Exp2) at a temporal resolution of 1 min (T pulse ¼ 0.8 ms; repetition time ¼ 8/7 ms; echo time ¼ 0.52 ms; bandwidth ¼ 150/175 Hz/pixel; 1 average; 7500/8570 projections Â 128 sampling points per projection; readout time ¼ 6.7/5.7 ms). 17 O MR images were reconstructed using Kaiser-Bessel gridding (46) without additional filtering of the raw data.
The volunteer inhaled 2.7 L (Exp1) and 2.5 L (Exp2) of 70%-enriched 17 O 2 gas (NUKEM Isotopes Imaging, Alzenau, Germany) via an oxygen gas delivery system with a RB circuit. Gas was administered in pulses of 40/50 mL using a non-MR safe demand oxygen delivery system (DODS) (Oxytron3; Weinmann, Hamburg, Germany), which efficiently delivers the rare and costly 17 O 2 gas to the alveoli by inspirational triggering.
The imaging experiment was divided into a baseline phase (10.5/9.2 min), wherein 17 O MR signal was acquired at natural abundance, followed by two phases with a closed RB system (Fig. 1a) : the DODS phase (5/4.2 min), wherein 17 O-enriched gas was delivered in pulses, and the RB phase (7.5/5.5 min), during which the volunteer was breathing the gas stored in the RB system (which contains the exhaled 17 O 2 gas that is then reused to increase the 17 O MR signal). In the final washout phase (25.1/22 min), the breathing system was opened and the volunteer was breathing room air.
Spatial Registration and Extraction of the 17 O Signal-Time Curves
For anatomical comparison and co-registration, a T 1 -weighted 3D 1 H MR image was acquired in a separate measurement with a standard MPRAGE sequence (repetition time ¼ 2300 ms; echo time ¼ 2.86 ms; inversion time ¼ 1100 ms; resolution ¼ 0.6 Â 0.6 Â 1 mm 3 ). First, both 17 O and 1 H MR images were interpolated onto 128 Â 128 Â 128 matrices. The 1 H data were then manually co-registered to the 17 O image, which was averaged over the whole MR examination, using anatomical landmarks that are visible in both images (e.g., the eyes, the ventricles, and the outer contour of the brain) to compensate for the different head positions in the 1 H and the 17 O coils. Rigid transformation consisting of translation and rotation in three directions was performed and a transformation matrix for 1 H images was obtained. Second, the software tool Statistical Parametric Mapping Package (SPM8) (47, 48) was used to segment gray matter (GM) and white matter (WM) brain regions in the original 1 H MPRAGE data of high spatial resolution. After this, the transformation matrix was applied to the 3D binary masks of WM and GM regions, the masks were then applied to the coregistered 17 O MR images. Finally, averaged 17 O MR signals were calculated for each tissue to obtain tissue-specific 17 O signal-time curves. Partial volume effects were not corrected in this study.
CMRO 2 Quantification Model
In the dynamic 17 O MRI experiment, the time evolution of the 17 O MR signal is observed. It can be assumed to be linearly correlated with the concentration of 17 O due to the short relaxation times (26, 37, 49 O concentration in mmol per gram tissue, the 17 O signal intensities before gas inhalation (i.e., during the baseline phase) were normalized using the H 2 17 O natural abundance of 20.56 mmol/g water , water partition coefficients [0.71 g/mL for WM and 0.83 g/mL for GM (50) ], and averaged density of brain tissue of 1.038 g/mL (51) .
Following the principle of mass conservation, the change of the H 2 17 O concentration within a given volume can be caused either by water creation and conversion to other intermediates in the volume, or inward and outward diffusion to or from neighboring volumes. Therefore, the CMRO 2 quantification model, as proposed by Atkinson and Thulborn (26) , describes the change OðtÞ:
Here, a is the 17 O enrichment fraction of the inhaled gas above natural abundance, and r ¼ 0.75 min À1 is the rate at which fresh 17 O binds to hemoglobin in the pulmonary (26) . T DODS denotes the beginning of the 17 O gas supply. The expected dynamic signal-time curve M H 17 2 O ðtÞ in the GM region is shown in Figure 1a based on the rate constants from Hoffmann (33) . Figure 1b shows the proposed time evolution of the enrichment fraction aðtÞ for the experiment with the RB circuit and a pulsed supply of 17 O gas. This curve takes into account that a small fraction of the 17 O 2 gas is exhaled, as it did not reach the alveoli. Exhaled 17 O 2 gas is stored in the RB circuit and is used up in subsequent inhalation cycles. Thus, during the DODS phase, in addition to the 17 O 2 gas being delivered by DODS pulses (a DODS ), re-inhalation of the exhaled 17 O 2 gas occurs, leading to a linear increase in a. Therefore, a linear increasing model with a slope s 1 was introduced. Similarly, in the RB phase, a was assumed to be linearly decreasing (s 2 ) to a RB . The CMRO 2 quantification model can be simplified by setting both slopes s 1 and s 2 to zero (Fig. 1c) , i.e. assuming constant a values (26, 33) , but it might lead to a reduced model fit quality. The advanced model with slopes s 1 and s 2 is hereafter compared with the simplified model with constant a values using the LR test (Eq. [6] ).
Model Analysis for CMRO 2 Quantification
Parameters of the pharmacokinetic model for CMRO 2 quantification were calibrated according to Equation [3] . The numerical optimization was conducted using the trust region-based optimization algorithm lsqnonlin implemented in MATLAB (MathWorks, Natick, Massachusetts, USA) (52) . In a nonlinear setting, multiple local optima are often present. Thus, a deterministic multistart was performed to find the global optimum (39) . All model analysis, optimization and uncertainty calculations were performed within the open-source and freely available MATLAB-based framework D2D (39) . Therein, the ODE solver CVODES from the SUNDIALS suite is used for ODE integration (53) . Following the model calibration, parameter uncertainties of the pharmacokinetic model were calculated. If the target parameter CMRO 2 was nonidentifiable, prior information based on estimation of the other model parameters was included to resolve the nonidentifiability. Thereby, a small amount of additional prior information was desired, because the measurement of the models prior is complex and implies additional sources of errors. The influence of the uncertainty of the prior information on the optimal CMRO 2 values, estimated through minimization of x 2 ðûÞ (Eq. [4] ), and on the calculated CIs (Eq. [5] ) was also investigated. In this case, relative CIs of CMRO 2 , which are the CIs of CMRO 2 divided by the optimal CMRO 2 values, were considered to account for different CMRO 2 values in various brain tissues.
To analyze the prediction capability of the advanced pharmacokinetic model for CMRO 2 , the following approach was taken: first, the model parameters CMRO 2 , K L , K G , a DODS , a RB , s 1 , and s 2 were allowed to vary (flat prior) within boundaries of À5 to 3 in log-space. If CMRO 2 was non-identifiable, a DODS was fixed to 0.27/ 0.31 (for Exp1/Exp2) based on the estimated amount of 17 O 2 inhaled with a single DODS pulse as in (27, 32) 2 , which include the optimum CMRO 2 value, were calculated using Equation [5] for the confidence level CL ¼ 0.33 and were used to present the calculated CMRO 2 values. It is worth noting that in this study the CMRO 2 values were presented for each dataset separately, and not as the range among several MR examinations.
RESULTS
An example of a 3D
17
O MRI data set with the co-registered 1 H MPRAGE image as well as WM and GM masks are shown in Figure 2 . The contour of the brain, which has higher water content than the rest of the head, as well as the eyes are clearly visible on 17 O MR images. The prototype custom-build coil was driven in the linear mode, which can cause L-R asymmetries in the excitation profile as seen in the posterior parts of the brain due to nonideal coil matching. These asymmetries, however, have only minor effects on CMRO 2 quantification, because H 2 17 O signal-time curves were obtained from large WM and GM regions and were normalized to the baseline before 17 O gas inhalation. The number of 17 O voxels within the GM region was 59.5 Á 10 3 , and 41.0 Á 10 3 within the WM region. The SNR of the MR images acquired within 1 min in the baseline phase were 6/4 for Exp1/ Exp2, thus the noise pattern can be assumed to be Gaussian (40) , as is presumed in Equation [2] . Figure 3 shows the calculated PLs of the parameters of the advanced CMRO 2 quantification model (in logspace), where all model parameters were set with a flat prior, i.e. no prior knowledge about a was assumed. The only quantifiable parameter was K L , since it determines the decay constant in the wash-out phase, when A 17 O is zero and B H 17 2 O is constant (Eq. [7] ). The target parameter CMRO 2 and the other model parameters were structurally non-identifiable. After assuming a constant value of a DODS (results not shown), CMRO 2 still remained nonidentifiable.
When the averaged a value during the DODS phase was taken as a constraint, the structural non-identifiability of parameters CMRO 2 , K G , and a RB was resolved (Fig. 4) . However, either a DODS or s 1 are practically non-identifiable 1160 Kurzhunov et al.
for each of the presented data sets. The profile of the parameter s 2 shows that a value of zero (i.e., a is constant during the RB phase) is consistent with the model without impairing the x 2 . The cyan dashed line represents the contribution of the chosen prior to the respective parameter profile. For example, the optimal CMRO 2 value is slightly left from the minimum of the chosen prior, and the CI of the parameters CMRO 2 and K G are dominated from the uncertainty of the prior. In contrast, the prior uncertainty has a much smaller impact on the CI of K L and s 2 .
Model fits for WM and GM regions are shown in Figure 5 , in which prior knowledge about the mean a value during the DODS phase was used. Here, CMRO 2 rates were 0.80-0.99/0.72-0.95 mmol/g tissue /min in WM and 1.02-1.27/1.21-1.78 mmol/g tissue /min in GM for Exp1/ Exp2 (Table 1) . Compared with the results of 15 O-PET studies (16), CMRO 2 rates were 34%-42% overestimated in WM and 9%-28% underestimated in GM (Table 1) . If one/two of the first DODS pulses are disregarded to account for the 94-mL dead volume of the cable connecting DODS system with nasal cannula (i.e., a later signal onset is assumed), 3%-4%/7%-8% higher CMRO 2 values were found.
In Figure 6 , the comparison of model calibration with the advanced and the simplified models is presented. The simplified model shows a stronger deviation from the data in the DODS phase than the advanced model, which is also reflected in the x 2 values: x 2 ¼ 40.0 (simplified) and x 2 ¼ 55.6 (advanced). From this, the LR test, described by Equation [6] , was calculated (P ¼ 4.1 Á 10 À4 < 0.05) showing a significant improvement with the advanced model. Moreover, the calculated CMRO 2 in the GM region with the simplified model of 1.11-1.59 mmol/g tissue /min is 9% and 18% underestimated compared with the advanced model and with the results of 15 O-PET studies (16) . Figure 7 shows how the a-uncertainty affects the relative CIs of CMRO 2 . In this case, CI, which is the difference between upper and lower boundaries of the calculated parameter, represents two standard deviations. These dependences are well represented by a quadratic polynomial, but the CIs are specific for each data set. For example, a 10% uncertainty in a leads to relative CIs of CMRO 2 of 0.22/0.28 for the WM region, and 0.23/ 0.40 for the GM region in Exp1/Exp2.
DISCUSSION
Altered oxygenation is found in brain tumors and neurodegenerative diseases. Thus, it is of high clinical interest to map oxygen metabolism in clinical routine. With the recent implementation of 17 O MRI (26, 27, (30) (31) (32) (33) , clinical CMRO 2 quantification and oxygen metabolism mapping might become feasible; however, the different parameters in the numerical description of the oxygen uptake are often not identifiable from time-resolved measurements alone. In this study, the PL method was used to identify those parameters in the CMRO 2 quantification model that require prior knowledge for a unique identification. , and s 2 À min
À1
; a DODS and a RB are dimensionless.
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The PL is an established method to assess parameter uncertainties in nonlinear settings (39, 41, 54) , where asymptotic CIs based on, for example, Fisher information are typically inappropriate (41) . The latter are exact if the solution of the model is linear in the parameters and are a good approximation for a large amount of data and low measurement noise. If these conditions are not fulfilled, the Fisher information is underestimating the true CI and cannot capture the nonlinearity effects outside the region near the optimum. In the 17 O MRI experiments, the SNR of the acquired MR images was SNR ¼ 4-6, leading to a relatively high measurement noise. Because the CMRO 2 quantification model is nonlinear, asymptotic CIs, which are commonly used in the least-square fitting algorithms, might be misleading.
Initially, the RB system was proposed in (27) , where a potential 17 O signal during RB phase was excluded from the data analysis due to complexity of the analytical solution of Equation [7] . Later, it was solved for constant a values (33) ; in this study, a numerical integration was used instead of solving the ODEs analytically. This numerical solution is beneficial for modeling of H 2 17 O signal-time curves because it is more flexible and can be used for more elaborate 17 O MRI experiments that, for example, use a lower amount of the rare 17 O 2 gas. Both the DODS and the RB circuit were used to efficiently deliver and use the rare and costly 17 O gas. Decreasing the amount of the 17 O gas required for a single patient experiment would directly reduce the total cost of 17 O MR examination, which might be an important aspect for clinical studies. The DODS is triggered internally by the patient's inhalation and efficiently delivers a precise and well-defined amount of 17 O gas for each inhalation. As originally discussed by Hoffmann et al. (27) , the risk of gas leakage and accidents in gas handling are minimized, because no transfer of the rare gas from the cylinder is required and standard, clinically approved breathing components can be used. The PL analysis showed that only one a-related parameter needs to be estimated in more complex CMRO 2 quantification model for the MR examination with DODS and RB phases, as it is the case for the experiment with RB phase only (26) . The parameters of the advanced model, s 1 and s 2 , are practically nonidentifiable but have no influence on either precision or uncertainty of the target parameter CMRO 2 . In this study, the advanced pharmacokinetic model for CMRO 2 quantification was used, which accounts for linearly varying enrichment fraction of the inhaled 17 O gas (Fig. 1b) . If all model parameters were initialized without prior information, the values of CMRO 2 and a were non-identifiable (Fig. 3) . Additional prior information about a DODS , which represents the 17 O enrichment from a DODS pulse, was not sufficient to quantify CMRO 2 . However, if the averaged a during the DODS phase was taken as prior, the structural non-identifiability of CMRO 2 was resolved (Fig. 4) . The identifiability is achieved because both a DODS , which describes the inhaled portion of 17 O gas from a fresh DODS pulse, and s 1 , which describes the additional amount of 17 O gas from the RB circuit, are constrained. This leads to an improved description of the nonlinear increase of M H 17 2 O ðtÞ through the change from a constant a to a more realistic input shape. In particular, the influence of the H 17 2 O gain via metabolism and diffusion from blood, which are both positive in Equation [7] , can be distinguished by the model and lead to a better description of the data. From an analysis of the parameter profiles, s 2 could be excluded from the model without affecting either the optima or the CIs of the other model parameters. A constant a value during the RB phase is equivalent to a closed RB system in which 17 O 2 gas is homogeneously distributed after the DODS phase and in which the 17 O fraction remains constant, although the total amount of oxygen decreases after each inhalation.
As can be seen in Figure 4 , either a DODS or s 1 are practically non-identifiable; however, this non-identifiability does not affect the identifiability of the target parameter CMRO 2 and the other model parameters. If s 1 is set to zero, the practical non-identifiability of a DODS is resolved. However, this simplified pharmacokinetic model with constant a values, which has been used previously (27, 32, 33) , led to a significant decrease of x 2 of the model up to 28% (Fig. 6) , whereas CI and optimal values of CMRO 2 were underestimated up to 9%. Thus, the use of the advanced model is beneficial even if not all model parameters can be fully identified.
In the simulation of different uncertainties for the prior information contained in a, a quadratic 15 O-PET studies (Table 1) . This is mainly caused by partial volume effects due to the low spatial resolution of 17 O MR images (Dx ¼ 10/8 mm for Exp1/Exp2) and fast transverse relaxation time T Ã 2 ¼ 2 ms. It increases the theoretical full width of half maximum of the point spread function (55) to 23%; an additional increase of 31% is caused by the radial acquisition of k-space. Thus, almost every pixel of 17 O images contains constitutes of several brain regions. The effect of this blurring of the CMRO 2 values is lower in Exp2 compared with Exp1, because the nominal spatial resolution of Exp2 was 20% higher. To overcome this limitation, a partial volume correction can be applied using, for example, a "geometric transfer matrix" algorithm as used by Hoffmann et al. (32) . Another alternative is to use prior information from the co-registered 1 H images of higher spatial resolution in the iterative reconstruction of 17 O MR images, which can be used for partial volume correction (31, 56) .
The CMRO 2 values obtained in 17 O MR experiments at UHFs (Table 1) were also affected by partial volume effects. At 9.4T, CMRO 2 of 0.64-0.86/1.37-1.47 mmol/g tissue/ min in WM/GM were found (26) . At 7T, CMRO 2 values of 0.50-0.89/0.80-1.61 mmol/g tissue /min in WM/GM were determined (27) , and the values had a higher uncertainty because data from the RB phase needed to be discarded, and an estimation of a needed to be provided. Pixel-wise CMRO 2 quantification is the ultimate goal of 17 O MR studies but thus far has been obtained only at 9.4T (26) . In this preliminary work at 3T, the SNR of the individual dynamic 17 O MR images obtained in 1-min intervals was not sufficient for pixel-wise CMRO 2 quantification. To increase SNR, an optimized 17 O quadrature coil is under construction and iterative image reconstruction using the mutual information from coregistered 1 H images [e.g., tissues boundaries (31, 56) ] can be used.
In contrast to models used previously (26, 27, 33) , profile likelihood allows addressing the amount of prior knowledge needed for robust CMRO 2 quantification. As shown by the structural identifiability in Figure 3 , an arbitrary value of CMRO 2 may be determined if no sufficient amount and quality of data are available or if the chosen model renders the parameter non-identifiable. Whenever a nonlinear model is used, the method of profile likelihood should be used to assess accurate uncertainties of the parameters. The practical advantage of the advanced model is the flexibility it gives for 17 O MR experiments. Because the model equations do not need to be solved analytically, more efficient and sophisticated 17 O gas handling can be modeled, as was the case for the DODS in this study. For example, in future improvements of the setup, the problem of the oxygen shortage at the end of the RB phase will be solved by switching to a 16 O gas supply during the RB phase, which can be included in the advanced quantification model. Thus, the volume of 16 O gas pulses can be adjusted to compensate for the losses in the RB circuit. In this case, a will significantly decrease and a RB can be calculated based on the amount of the supplied 16 O gas. In general, the profile likelihood approach might also be of interest to investigate identifiability of model parameters in other fields of MRI, as e.g. in dynamic MRI examinations with contrast agent injections, or it could help in other medical imaging techniques, like PET, where tracer kinetics are modeled to determine physiological parameters. In conclusion, the results of the profile likelihood analysis show that CMRO 2 can be measured reliably in 17 O MRI experiment with 17 O gas inhalation if the 17 O enrichment fraction is estimated based on the experimental system and introduced as prior information into the model calculations.
